Furthermore, melanoma cells, regardless of their BRAF or NRAS mutation status, are sensitive to the growth inhibitory effects of 17-AAG (21), consistent with the action of Hsp90 inhibitors on multiple oncoproteins, including CRAF. The gene discussed is NRAS; the disease is melanoma.